
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech's substantial cash position of approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables provides the company with a solid financial foundation to support its ongoing research and development initiatives. The positive developments surrounding BNT323, as well as promising data from its monovalent COVID-19 vaccine, suggest potential advancements in both oncology and infectious disease areas, further strengthening its portfolio. This combination of strong financial backing and favorable pipeline progress contributes to a positive outlook for BioNTech's stock.
Bears say
BioNTech's outlook is challenged by a series of risks, including negative data from multiple candidates within its oncology pipeline and slower market uptake for its products. The company reported a net loss per diluted share of €0.12 for Q3 2025, with projections indicating a full-year loss of €3.99, signaling ongoing financial struggles. Additionally, investor focus may be diverted from BioNTech's oncology efforts due to the evolving dynamics within the COVID-19 vaccine market, influenced by regulatory changes in the U.S.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares